Care Navigation

The $26,000 Placebo: Why the New Alzheimer’s Drugs Are a Rich Man’s Illusion

Leqembi and Kisunla promise to slow down cognitive decline, but the real-world math, side effects, and hidden care facility costs tell a far darker story.

By Neil D'Monte, Palmelle Editorial Team · Reviewed by Neil D'Monte · 7 min read · 2026-07-07

Imagine writing a check for twenty-six thousand dollars every single year for a drug that does not make your mother’s memory any better. It does not stop her dementia, it does not restore the keys she lost, and it will not bring back the woman who recognized your voice last Thanksgiving. Instead, it promises to delay the inevitable by about five months, assuming she survives the brain bleeding first.

SHORT ANSWER

These drugs do not fix memory loss, but they will reliably drain your bank account and complicate your parent's remaining years with constant hospital visits.

The direct answer

The brand-new FDA-approved Alzheimer’s drugs, Leqembi and Kisunla, do not cure or reverse cognitive decline; they merely slow it down by roughly 22% to 35% over 18 months, which translates to a few months of status quo. For most families, this marginal delay is erased by the immense physical toll of regular brain scans, the risk of brain swelling, and thousands in out-of-pocket costs that insurance refuses to cover. If your parent is already transitioning into a care facility, that money is far better spent securing high-quality, hands-on attention than chasing a chemical mirage.

The Brutal Math of a Five-Month Delay

Let’s look at the numbers because the marketing departments at Eisai and Eli Lilly certainly do not want you to.

Leqembi costs roughly $26,500 per year, and Kisunla sits at about $32,000 annually.

These figures do not include the cost of the bi-weekly intravenous infusions, the neurologists, or the repeated MRI scans required to monitor for brain swelling.

In the drug trials, these medications cleared amyloid plaques from the brain, which sounds spectacular on a PowerPoint slide.

But in real life, the actual cognitive benefit was a fraction of a point on an 18-point scale.

To the average family, this means your parent might keep the ability to button their shirt for an extra eighteen weeks, but they will still eventually lose their memory.

Medicare does cover some of this, but only if your doctor participates in a federal registry and you meet strict criteria.

If you are in the 20% co-insurance gap, you are still looking at over $5,000 a year just for the drug itself, before the infusion center bills you.

That is a lot of money for a promise that comes with a warning label about brain bleeding.

The Hidden Care Facility Tax on 'Miracle' Drugs

If your parent lives in a care facility, the true cost of these drugs skyrockets behind closed doors.

Most assisted living facilities are not equipped to handle bi-weekly intravenous infusions, meaning you must pay for private transport to an infusion center or pay the facility's third-party nursing rate.

Furthermore, when you review federal CMS and state inspection data, you quickly realize that understaffed homes struggle with basic medication management, let alone monitoring for the severe side effects of these new drugs.

Amyloid-related imaging abnormalities, or ARIA, occur in up to a third of people taking these drugs, requiring immediate, highly coordinated care that a typical facility simply cannot provide.

Paid referral platforms like A Place for Mom or Caring.com will never tell you this because they only show you facilities that pay them commissions.

They omit the critical detail that a facility might have a terrible Palmelle Clarity Score of 42, indicating a history of medication errors that makes administering a high-risk drug like Leqembi downright dangerous.

If the staff cannot consistently deliver a daily blood pressure pill on time, they are not going to catch the early signs of a drug-induced brain bleed.

Where to Actually Spend Your Care Dollars

Instead of spending $5,000 to $15,000 a year out-of-pocket on a drug that buys five months of marginal stability, look at what that same money buys in actual human support.

That capital can fund an extra twenty hours a week of one-on-one help, allowing your parent to stay in their familiar home environment much longer.

At Palmelle, we help families make these cold, hard trade-offs without the emotional manipulation of big pharma or commission-hungry referral sites.

Our Help Me Choose service costs $199 and gives you an unbiased, data-backed roadmap to finding care facilities that actually have the staffing ratios to keep your parent safe.

If you are trying to keep your parent at home, our CAPS aging-in-place Assessment is $399 and identifies the exact physical modifications and local resources needed to prevent the falls that send dementia residents to the hospital far faster than plaque buildup ever will.

For hands-on help vetting local agencies, you can explore our curated directory at /home-services.

Your money is finite, and your parent's time is even scarcer.

Do not trade real, tangible daily care for a chemical long shot.

Common mistakes

Assuming Medicare covers the entire bill
Medicare covers 80% of the drug cost under Part B, leaving you with a $5,000+ annual co-pay. Add in the cost of mandatory MRIs and infusion center fees, and the out-of-pocket total can easily exceed $10,000 annually.
Trusting a care facility's promise to manage the drug regimen
Many facilities lack the nursing staff to monitor for ARIA (brain bleeding) symptoms. Always check federal CMS and state inspection data, or look up the facility's Palmelle Clarity Score, to see if they have a history of medication administration violations before starting treatment.

PALMELLE'S VIEW

We believe these new drugs are an expensive distraction from the real work of care. True quality of life for someone with dementia does not come from a vial; it comes from safe environments, highly staffed memory care, and keeping their daily routine intact.

BOTTOM LINE

Do not let the promise of a miracle drug distract you from the practical reality of daily care. A well-staffed, safe environment will always do more for your parent’s daily happiness than a high-priced drug with a laundry list of side effects. Invest your resources where they can actually be felt: in the hands that hold theirs every day.

WHEN THIS CHANGES

This advice changes if your parent has an extremely rare, early-onset genetic form of Alzheimer's and has access to a top-tier academic hospital trial where all costs, including MRIs and travel, are fully covered by a research grant.

Frequently asked

Does insurance cover Leqembi and Kisunla for dementia?

Medicare Part B covers 80% of the cost, but only if the person has mild cognitive impairment or early-stage dementia and their doctor participates in a qualifying registry. Private insurance coverage varies wildly, and many plans require extensive prior authorizations that can take months to approve.

What are the actual side effects of these new Alzheimer's drugs?

The primary risk is ARIA, which involves temporary swelling or small bleeds in the brain. In drug trials, about 20% to 30% of people experienced ARIA, and while most cases were asymptomatic, some were severe or even fatal, requiring regular MRI scans to monitor safety.

How do I know if a memory care facility can handle someone on these drugs?

Do not ask the sales director; look at the hard data. Check the federal CMS and state inspection data for citations related to medication administration and nursing hours. A Palmelle Clarity Score below 70 is a major red flag that the facility may lack the staff to safely monitor high-risk treatments.